Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds

G. Mózsik, Zsanett Peidl, J. Szolcsányi, András Dömötör, K. Hideg, György Szekeres, Oszkár Karádi, B. Hunyady

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The effects of omeprazole and different omeprazole-like compounds, associated with anti-ischaemic, antioxidant and poly(adenosine-diphosphate- ribose) polymerase (PARP) inhibitory properties, on the gastric acid secretion (4 h pylorus-ligated) and indomethacin-induced gastric mucosal damage connected with the specific immunohistochemical distribution of TRPV1, CRGP and SP during the effects of these compounds, were studied. The observations were carried out in CFY-strain rats (180-210 g), according to the standard methods and the above-mentioned parameters were studied in these experimental circumstances without and with application of different compounds. We found that: (1) all of the compounds dose-dependently inhibited the gastric acid secretion and mucosal damage; (2) the expression of TRPV1 receptor, CGRP and SP decreased significantly in both pylorus-ligated and indomethacin-treated animals and (3) the expression of TRPV1 and CGRP was reduced. Meanwhile, no change was obtained in SP expression during the gastric mucosal protection produced by omeprazole and omeprazole-like compounds. The conclusions were that (1) a functional overlap exists between the capsaicin-sensitive afferent and efferent vagal nerve during omeprazole effects; (2) chemical modification of omeprazole molecule offers a new pathway to obtain a new drug for the introduction in the clinical practice.

Original languageEnglish
Pages (from-to)139-159
Number of pages21
JournalInflammopharmacology
Volume13
Issue number1-3
DOIs
Publication statusPublished - 2005

Fingerprint

TRPV Cation Channels
Omeprazole
Calcitonin Gene-Related Peptide
Substance P
Stomach
Gastric Acid
Pylorus
Indomethacin
Poly Adenosine Diphosphate Ribose
Capsaicin
peptide P
Antioxidants
Pharmaceutical Preparations

Keywords

  • Calcitonin-gene-related peptide (CGRP)
  • Omeprazole
  • Omeprazole-like compound
  • Substance P
  • Transient receptor potential vanilloid 1 (TRPV1)

ASJC Scopus subject areas

  • Pharmacology
  • Immunology

Cite this

Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds. / Mózsik, G.; Peidl, Zsanett; Szolcsányi, J.; Dömötör, András; Hideg, K.; Szekeres, György; Karádi, Oszkár; Hunyady, B.

In: Inflammopharmacology, Vol. 13, No. 1-3, 2005, p. 139-159.

Research output: Contribution to journalArticle

@article{564da2e51c6746caaa5f46eae4d58096,
title = "Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds",
abstract = "The effects of omeprazole and different omeprazole-like compounds, associated with anti-ischaemic, antioxidant and poly(adenosine-diphosphate- ribose) polymerase (PARP) inhibitory properties, on the gastric acid secretion (4 h pylorus-ligated) and indomethacin-induced gastric mucosal damage connected with the specific immunohistochemical distribution of TRPV1, CRGP and SP during the effects of these compounds, were studied. The observations were carried out in CFY-strain rats (180-210 g), according to the standard methods and the above-mentioned parameters were studied in these experimental circumstances without and with application of different compounds. We found that: (1) all of the compounds dose-dependently inhibited the gastric acid secretion and mucosal damage; (2) the expression of TRPV1 receptor, CGRP and SP decreased significantly in both pylorus-ligated and indomethacin-treated animals and (3) the expression of TRPV1 and CGRP was reduced. Meanwhile, no change was obtained in SP expression during the gastric mucosal protection produced by omeprazole and omeprazole-like compounds. The conclusions were that (1) a functional overlap exists between the capsaicin-sensitive afferent and efferent vagal nerve during omeprazole effects; (2) chemical modification of omeprazole molecule offers a new pathway to obtain a new drug for the introduction in the clinical practice.",
keywords = "Calcitonin-gene-related peptide (CGRP), Omeprazole, Omeprazole-like compound, Substance P, Transient receptor potential vanilloid 1 (TRPV1)",
author = "G. M{\'o}zsik and Zsanett Peidl and J. Szolcs{\'a}nyi and Andr{\'a}s D{\"o}m{\"o}t{\"o}r and K. Hideg and Gy{\"o}rgy Szekeres and Oszk{\'a}r Kar{\'a}di and B. Hunyady",
year = "2005",
doi = "10.1163/156856005774423764",
language = "English",
volume = "13",
pages = "139--159",
journal = "Inflammopharmacology",
issn = "0925-4692",
publisher = "Birkhauser Verlag Basel",
number = "1-3",

}

TY - JOUR

T1 - Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds

AU - Mózsik, G.

AU - Peidl, Zsanett

AU - Szolcsányi, J.

AU - Dömötör, András

AU - Hideg, K.

AU - Szekeres, György

AU - Karádi, Oszkár

AU - Hunyady, B.

PY - 2005

Y1 - 2005

N2 - The effects of omeprazole and different omeprazole-like compounds, associated with anti-ischaemic, antioxidant and poly(adenosine-diphosphate- ribose) polymerase (PARP) inhibitory properties, on the gastric acid secretion (4 h pylorus-ligated) and indomethacin-induced gastric mucosal damage connected with the specific immunohistochemical distribution of TRPV1, CRGP and SP during the effects of these compounds, were studied. The observations were carried out in CFY-strain rats (180-210 g), according to the standard methods and the above-mentioned parameters were studied in these experimental circumstances without and with application of different compounds. We found that: (1) all of the compounds dose-dependently inhibited the gastric acid secretion and mucosal damage; (2) the expression of TRPV1 receptor, CGRP and SP decreased significantly in both pylorus-ligated and indomethacin-treated animals and (3) the expression of TRPV1 and CGRP was reduced. Meanwhile, no change was obtained in SP expression during the gastric mucosal protection produced by omeprazole and omeprazole-like compounds. The conclusions were that (1) a functional overlap exists between the capsaicin-sensitive afferent and efferent vagal nerve during omeprazole effects; (2) chemical modification of omeprazole molecule offers a new pathway to obtain a new drug for the introduction in the clinical practice.

AB - The effects of omeprazole and different omeprazole-like compounds, associated with anti-ischaemic, antioxidant and poly(adenosine-diphosphate- ribose) polymerase (PARP) inhibitory properties, on the gastric acid secretion (4 h pylorus-ligated) and indomethacin-induced gastric mucosal damage connected with the specific immunohistochemical distribution of TRPV1, CRGP and SP during the effects of these compounds, were studied. The observations were carried out in CFY-strain rats (180-210 g), according to the standard methods and the above-mentioned parameters were studied in these experimental circumstances without and with application of different compounds. We found that: (1) all of the compounds dose-dependently inhibited the gastric acid secretion and mucosal damage; (2) the expression of TRPV1 receptor, CGRP and SP decreased significantly in both pylorus-ligated and indomethacin-treated animals and (3) the expression of TRPV1 and CGRP was reduced. Meanwhile, no change was obtained in SP expression during the gastric mucosal protection produced by omeprazole and omeprazole-like compounds. The conclusions were that (1) a functional overlap exists between the capsaicin-sensitive afferent and efferent vagal nerve during omeprazole effects; (2) chemical modification of omeprazole molecule offers a new pathway to obtain a new drug for the introduction in the clinical practice.

KW - Calcitonin-gene-related peptide (CGRP)

KW - Omeprazole

KW - Omeprazole-like compound

KW - Substance P

KW - Transient receptor potential vanilloid 1 (TRPV1)

UR - http://www.scopus.com/inward/record.url?scp=27744514641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744514641&partnerID=8YFLogxK

U2 - 10.1163/156856005774423764

DO - 10.1163/156856005774423764

M3 - Article

C2 - 16259735

AN - SCOPUS:27744514641

VL - 13

SP - 139

EP - 159

JO - Inflammopharmacology

JF - Inflammopharmacology

SN - 0925-4692

IS - 1-3

ER -